A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Summary

The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for human immunodeficiency virus 1 (HIV-1) infection.

Timeline

Start

2022-10-17

Primary completion

2024-03-25

Completion

2024-03-25

Drugs

Indications